Karl S Peggs

Summary

Affiliation: University College London
Country: UK

Publications

  1. pmc Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    S A Quezada
    Cancer Immunology Unit, Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
    Br J Cancer 108:1560-5. 2013
  2. doi request reprint Management of multidrug-resistant viruses in the immunocompromised host
    Rob S Sellar
    Department of Haematology, University College London Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK
    Br J Haematol 156:559-72. 2012
  3. ncbi request reprint Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley Street, London, WC1E 6BT, UK
    Expert Rev Anticancer Ther 10:1697-701. 2010
  4. pmc Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
    K S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, London, UK
    Clin Exp Immunol 157:9-19. 2009
  5. ncbi request reprint Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley Street, London, WC1E 6BT, UK
    Expert Rev Anticancer Ther 11:1667-70. 2011
  6. doi request reprint HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
    Adam J Mead
    Department of Haematology, University College London UCL Medical School, London, United Kingdom
    Blood 115:5147-53. 2010
  7. ncbi request reprint Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
    Simon E Richardson
    Royal Free Hampstead NHS Trust, London, UK
    Br J Haematol 160:640-8. 2013
  8. ncbi request reprint Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy
    Karl S Peggs
    Department of Haematology, Royal Free and University College London Medical School, London, United Kingdom
    Hum Immunol 65:550-7. 2004
  9. doi request reprint Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley St, London WC1E 6BT United Kingdom
    J Clin Oncol 29:971-8. 2011
  10. ncbi request reprint Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
    Karl S Peggs
    Department of Haematology, Royal Free and University College, London, UK
    Br J Haematol 139:70-80. 2007

Collaborators

Detail Information

Publications48

  1. pmc Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    S A Quezada
    Cancer Immunology Unit, Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
    Br J Cancer 108:1560-5. 2013
    ..This mini-review will focus on attempts to target co-inhibitory members of the immunoglobulin superfamily...
  2. doi request reprint Management of multidrug-resistant viruses in the immunocompromised host
    Rob S Sellar
    Department of Haematology, University College London Cancer Institute, 72 Huntley Street, London WC1E 6DD, UK
    Br J Haematol 156:559-72. 2012
    ..We also outline some of the newer agents and treatment strategies being developed to treat multidrug-resistant viruses...
  3. ncbi request reprint Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley Street, London, WC1E 6BT, UK
    Expert Rev Anticancer Ther 10:1697-701. 2010
    ....
  4. pmc Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
    K S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, London, UK
    Clin Exp Immunol 157:9-19. 2009
    ....
  5. ncbi request reprint Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley Street, London, WC1E 6BT, UK
    Expert Rev Anticancer Ther 11:1667-70. 2011
    ....
  6. doi request reprint HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
    Adam J Mead
    Department of Haematology, University College London UCL Medical School, London, United Kingdom
    Blood 115:5147-53. 2010
    ..44). Mismatch occurred at the antigenic level in 40 cases. The outcome in these cases did not differ significantly from the rest of the cohort. We conclude that RIT using HLA-mismatched grafts is a viable option using FMC conditioning...
  7. ncbi request reprint Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
    Simon E Richardson
    Royal Free Hampstead NHS Trust, London, UK
    Br J Haematol 160:640-8. 2013
    ..In conclusion, the directed delivery of allogeneic cellular therapy has the potential to induce durable remissions in high-risk CLL without incurring excessive GVHD...
  8. ncbi request reprint Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy
    Karl S Peggs
    Department of Haematology, Royal Free and University College London Medical School, London, United Kingdom
    Hum Immunol 65:550-7. 2004
    ..This simple in vitro methodology should allow widespread application of adoptive transfer of virus-specific T cells...
  9. doi request reprint Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley St, London WC1E 6BT United Kingdom
    J Clin Oncol 29:971-8. 2011
    ..We aimed to assess the impact of donor lymphocyte infusions (DLIs) on relapse incidence when administered for mixed chimerism and their utility as salvage therapy when given for relapse...
  10. ncbi request reprint Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
    Karl S Peggs
    Department of Haematology, Royal Free and University College, London, UK
    Br J Haematol 139:70-80. 2007
    ....
  11. ncbi request reprint High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma
    Adrian J C Bloor
    Department of Haematology, Royal Free and University College London School of Medicine, London, United Kingdom
    Biol Blood Marrow Transplant 14:50-8. 2008
    ..These data support the existence of a clinically significant graft-versus-tumor effect in indolent NHL and suggest that this is an effective treatment for progressive disease after allogeneic SCT...
  12. doi request reprint T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma
    Kirsty J Thomson
    Department of Haematology, University College Hospital, London, UK
    J Clin Oncol 28:3695-700. 2010
    ..Thus, reduced-intensity conditioning regimens are being explored...
  13. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003
    ..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations...
  14. ncbi request reprint Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure
    Jaimal Kothari
    Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
    Br J Haematol 165:334-40. 2014
    ..Our data shows that BEAM ASCT can be a highly effective treatment in patients with FL early in the disease course, and that a proportion of patients experience prolonged disease-free survival and may be cured...
  15. ncbi request reprint Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation
    Karl S Peggs
    Department of Haematology, UCL Medical School, University College London, London, United Kingdom
    Clin Infect Dis 49:1851-60. 2009
    ....
  16. ncbi request reprint Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
    Karl S Peggs
    Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
    Blood 103:1548-56. 2004
    ....
  17. ncbi request reprint Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
    Karl S Peggs
    Royal Free and University College London Medical School, London, UK
    Lancet 362:1375-7. 2003
    ..Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment...
  18. ncbi request reprint Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure
    Sajir G Mohamedbhai
    Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
    Br J Haematol 156:516-22. 2012
    ....
  19. ncbi request reprint Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma
    Jonathan R Lambert
    Department of Haematology, University College London Cancer Institute, London, UK
    Blood 115:2763-8. 2010
    ....
  20. ncbi request reprint Reduced intensity transplantation: where are we now?
    Stephen Mackinnon
    Royal Free and University College London, London, UK
    Hematol J 5:S34-8. 2004
  21. ncbi request reprint The role of allogeneic transplantation in non-Hodgkin's lymphoma
    Karl S Peggs
    Department of Haematology, Royal Free and University College London Medical Schools, London, UK
    Br J Haematol 128:153-68. 2005
    ....
  22. doi request reprint Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning
    William M Townsend
    Department of Haematology, University College London Hospitals NHS Foundation Trust and UCL Medical School, London, UK
    Br J Haematol 161:578-86. 2013
    ..Reduced intensity Allo-HSCT patients admitted to ICU with critical illness have improved survival compared to myeloablative Allo-HSCT recipients...
  23. ncbi request reprint Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
    Karl S Peggs
    Department of Haematology, Royal Free and University College London, UK
    Lancet 365:1934-41. 2005
    ..Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation...
  24. doi request reprint Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation
    Rob S Sellar
    UCL Cancer Institute, Department of Haematology, London, WC1E 6BT, UK
    Future Oncol 8:1549-65. 2012
    ....
  25. doi request reprint Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Medical School, University College London, London, United Kingdom
    Clin Infect Dis 52:49-57. 2011
    ..The logistics of producing virus-specific T cells has, however, limited the application of cellular therapies, particularly following the introduction of more-recent regulatory stipulations...
  26. doi request reprint Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
    Claire Roddie
    UCL Cancer Institute, Department of Haematology, Paul O Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK
    Expert Opin Biol Ther 11:473-87. 2011
    ..Infusion of donor lymphocytes can potentially enhance immune-mediated antitumor activity and offers a salvage option for some patients. This paper reviews the current literature on the efficacy of this therapeutic strategy...
  27. ncbi request reprint Role of allogeneic stem cell transplantation in multiple myeloma
    Kirsty J Thomson
    Department of Hematology, University College London Hospitals, London, UK
    Expert Rev Anticancer Ther 5:455-64. 2005
    ..This review aims to examine the current position of allogeneic transplantation in the management of myeloma...
  28. doi request reprint Allogeneic transplantation for Hodgkin lymphoma
    Karl S Peggs
    Department of Haematology, University College London Cancer Institute, London, UK
    Br J Haematol 143:468-80. 2008
    ..This review focuses on evaluating recent experience with reduced intensity allogeneic approaches in HL in order to inform opinion on its current role and to highlight areas for future investigation...
  29. ncbi request reprint Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, University College London, London, UK
    Immunol Rev 224:141-65. 2008
    ....
  30. doi request reprint Allogeneic transplantation in the UK: an aggregation of marginal gains?
    Kirsty J Thomson
    Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
    Br J Haematol 163:149-59. 2013
    ....
  31. doi request reprint Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults
    Jonathan I Sive
    Department of Haematology, University College London Hospital, UK
    Clin Infect Dis 55:1362-70. 2012
    ..However, the true incidence and clinical significance as well as the relationship of disease to viremic titer remain unclear due to wide variation in study populations and methodology...
  32. doi request reprint Therapeutic strategies for the prevention and treatment of cytomegalovirus infection
    Rob S Sellar
    UCL Cancer Institute, Department of Haematology, WC1E 6BT, London, UK
    Expert Opin Biol Ther 12:1161-72. 2012
    ..There is a clear rationale for the restoration of CMV-specific immunity using adoptive T-cell immunotherapy...
  33. ncbi request reprint Improving cellular therapies in Epstein - Barr virus-associated Hodgkin's lymphoma: shifting the equilibrium between effectors and regulators
    Karl S Peggs
    Department of Haematology, Royal Free and University College London Medical Schools, London, UK
    Leuk Lymphoma 47:787-9. 2006
  34. ncbi request reprint Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy
    Karl S Peggs
    Department of Hematology, Royal Free and University College London Medical School, 98 Chenies Mews, London, WC1E 6HX, UK
    Expert Rev Anti Infect Ther 2:559-73. 2004
    ..Efforts have therefore focused on molecular diagnostic surveillance protocols that allow earlier intervention and the development of adoptive immunotherapeutic strategies to hasten host immune reconstitution...
  35. ncbi request reprint Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects
    Shirley D'Sa
    Department of Haematology, University College London Hospitals NHS Trust, London, UK
    Br J Haematol 125:756-65. 2004
    ..We conclude that ESHAP has acceptable toxicity and efficient stem cell mobilizing capability, effectively cytoreduced this chemoresistant group of patients, and did not appear to adversely affect transplant outcome...
  36. ncbi request reprint Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection
    Karl S Peggs
    Department of Haematology, University College London, London, United Kingdom
    Biol Blood Marrow Transplant 9:198-205. 2003
    ....
  37. doi request reprint Adoptive T cell immunotherapy for cytomegalovirus
    Karl S Peggs
    UCL Cancer Institute, Department of Haematology, Paul O Gorman Building, 72 Huntley Street, London WC1E 6BT, UK
    Expert Opin Biol Ther 9:725-36. 2009
    ....
  38. ncbi request reprint Cytomegalovirus: the role of CMV post-haematopoietic stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College Hospital, London WC1E 6HX, UK
    Int J Biochem Cell Biol 36:695-701. 2004
    ..Efforts have therefore focused on molecular diagnostic surveillance protocols that allow earlier intervention, and the development of adoptive immunotherapeutic strategies to hasten host immune reconstruction...
  39. ncbi request reprint Adoptive cellular therapy: a therapeutic reality?
    Karl S Peggs
    Department of Haematology, University College Hospital, London, UK
    Hematology 7:127-36. 2002
    ..This review summarizes these developments and highlights some of the issues that remain to be resolved...
  40. doi request reprint The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation
    Rob S Sellar
    Department of Haematology, University College London, London, UK
    Cytotherapy 14:391-400. 2012
    ....
  41. ncbi request reprint Immune reconstitution following haematopoietic stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 124:407-20. 2004
  42. ncbi request reprint Immune reconstitution following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, UK
    Leuk Lymphoma 45:1093-101. 2004
    ..This review focuses mainly on recent advances in the understanding of immune reconstitution in the allogeneic setting...
  43. doi request reprint Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
    Marco Gerlinger
    Cancer Research UK, London Research Institute, UK Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, London, UK
    J Pathol 231:424-32. 2013
    ..These were polyclonal and displayed ITH in ccRCC. TCRb sequencing may shed light on mechanisms of cancer immunity and the efficacy of immunotherapy approaches...
  44. ncbi request reprint Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update
    Rob S Sellar
    UCL Cancer Institute, Department of Haematology, London, WC1E 6BT, UK
    Expert Opin Biol Ther 14:1121-6. 2014
    ....
  45. doi request reprint PD-1 blockade: promoting endogenous anti-tumor immunity
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, Paul O Gorman Building, University College London, 72 Huntley Street, London WC1E 6BT, UK
    Expert Rev Anticancer Ther 12:1279-82. 2012
    ..After a long wait, it finally seems that immune-based anticancer therapies are emerging to become part of the mainstream...
  46. ncbi request reprint Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
    Emma C Morris
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK
    Blood 102:404-6. 2003
    ..Total lymphocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantation (P =.005), and median absolute CD4 counts higher than 200 x 106/L were delayed until 9 months after transplantation...
  47. ncbi request reprint Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London, London, UK
    Br J Haematol 120:154-65. 2003
    ..The novel and objective diversity scoring system described appears better able to document changes in spectratype patterns than previously described techniques and should aid the standardization of reporting...
  48. ncbi request reprint Role of MabCampath in allogeneic transplantation
    K S Peggs
    Royal Free and University College London Medical School, London, UK
    Ann Hematol 83:S66-8. 2004
    ..Disease relapse appears more common but approaches incorporating DLI may offset this tendency in immune responsive malignancies. Delivery of these therapies in a less toxic manner remains a priority for future research...